Company profile
UK company 09526225, incorporated on 7 April 2015.
NuVision Biotherapies -Innovative therapies for ocular surface disease
Omnigen is our wound dressing and grafting material. OmniLenz bespoke contact lensfor rapid surgery free care.
Company number 09526225
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating 'front of the eye' disease and trauma.
Mercia Fund Management has provided £379,000 in seed funding to help NuVision commercialise its ground-breaking product.
1 Mar 2023 to 31 Aug 2024
In a rapidly ageing global population, dry eye disease (DED) affects up to 50% of the global adult population, and 15-33% of people aged ≥65 years, with ~5.6m UK adults experiencing moderate-to-severe symptoms. DED is an incurable chronic age-related-condition that is a major cause of eye problems, frequent visits to eye-care practitioners, patient distre...
1 Jun 2020 to 28 Feb 2021
no public description
1 Mar 2018 to 31 Dec 2020
Amniotic membrane or amnion (the inner layer of the sac a baby grows in) has been used to treat wounds in eyes, skin and internal organs since the 1940s. NuVision(r) Biotherapies Ltd is a company spun out from the University of Nottingham Ophthalmology department to commercialise Omnigen(r). Expectant mothers who have planned caesarians can donate their a...
1 Nov 2015 to 31 Mar 2017
There are millions of corneal trauma cases globally each year. Without effective treatment, ocular surface trauma can progress to long term complication and corneal blindness. Amniotic membrane has been used in ophthalmic surgery to treat disease and damage to the surface of the eye. Unfortunately clinical usage of amnion has been severely limited as it i...
